表 1.
文献回顾SCLC合并腺癌患者临床特征文献回顾
Literature review of clinical features of the patients with SCLC complicated with adenocarcinoma
| Reference | Age/Gender | Smoking | Pathological diagnosis | Diagnosis specimen type | Mutation gene | Stage | Treatment | Response | OS (mon) |
| †: staging details not specific. ADC: adenocarcinoma; SCLC: small cell lung cancer; ED: extensive disease; OS: overall survival; EML4-ALK: echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase; F: female; M: male. | |||||||||
| Tatematsu et al[26] | 69/M | Yes | SCLC/ADC | Biopsy specimen | EGFR L858R | Ia | Surgery and adjuvant chemotherapy | - | - |
| Tatematsu et al[26] | 65/M | Yes | SCLC/ADC | Resected tumor (cytological diagnosis of SCLC prior to surgery) | EGFR Ex19del | Ia | Adjuvant chemotherapy and radiotherapy | - | - |
| Tatematsu et al[26] | 36/F | No | SCLC/ADC | Resected tumor (diagnosis of ADC with a biopsy prior to surgery) | EGFR L858R | IV | Surgery | - | - |
| Siegele et al[27] | 82/M | Yes | SCLC/ADC | Resected tumor | EGFR D855H | Ia | Surgery and adjuvant chemotherapy | - | Lost to follow up |
| Shi et al[28] | 71/M | Yes | SCLC/ADC | Resected tumor | EGFR L858R | I† | Surgery | - | 12 |
| Lu et al[29] | 62/F | No | SCLC/ADC | Resected tumor | EGFR Ex19del | IIIa | Surgery | - | - |
| Wakuda et al[30] | 73/M | Yes | SCLC/ADC | Resected tumor | EGFR G719A | IIb | Surgery | - | - |
| Iijima et al[31] | 63/M | Yes | SCLC/ADC | Resected tumor | EGFR Ex19del | IIb | Surgery | - | - |
| Iijima et al[31] | 76/M | Yes | SCLC/ADC | Resected tumor | EGFR Ex19del | IIIa | Surgery | - | - |
| Lu et al[20] | 62/F | No | SCLC/ADC | Resected tumor | EGFR Ex19del | IIIa | Surgery and adjuvant chemotherapy | - | 22 |
| Norkowski et al[32] | 66/F | Yes | SCLC/ADC | Resected tumor | EGFR Ex19del | IIIa | - | - | 120 |
| Norkowski et al[32] | 62/M | No | SCLC/ADC | Resected tumor | EGFR Exon 18 G719A, Exon 21 L833_V834delinsFL | IIIa | - | - | 8 |
| Norkowski et al[32] | 45/F | Yes | SCLC/ADC | Resected tumor | Exon 21 L858R | IIIa | - | - | 12 |
| Ye Guo et al[22] | 61/M | Yes | SCLC/ADC | Biopsy specimen | EGFR Ex19del | ED | Chemotherapy and Erlotinib | SD | - |
| Fukui et al[33] | 62/F | No | SCLC/ADC | Resected tumor | EGFR L858R | IIIb | Surgery | - | - |
| Lin et al[10] | 66/F | No | SCLC/ADC | Resected tumor | EGFR L858R | IIIa | - | - | - |
| Lin et al[10] | 77/F | No | SCLC/ADC | Resected tumor | EGFR L858R | IIIa | Erlotinib | NS | - |
| Lin et al[10] | 63/F | No | SCLC/ADC | Resected tumor | EGFR G719A | IVb | Afatinib | NS | - |
| Takagi et al[34] | 70/F | No | SCLC/ADC | Biopsy specimen | EGFR L861Q | IVb | Chemotherapy | PR | - |
| Tanaka et al[23] | 67/M | No | SCLC/ADC | Biopsy specimen | EGFR Ex19del | IVb | Chemotherapy and Afatinib | PR | - |
| Toyokawa et al[15] | 72/M | Yes | SCLC/ADC | Resected tumor | EGFR Ex19del, EML4-ALK | Ib | Surgery | - | - |